Mitesh

The NHS Business Services Authority (NHSBSA) produces a quarterly newsletter called “Hints & Tips for dispensing contractors”. The latest edition (Issue 55) contains some useful information and advice on: Prescription switching – reduce the chances of it happening to you NHS Prescription Prepayment Certificates (PPC) Medicines covered by the Hormone Replacement Therapy Prescription Prepayment Certificate [...]

The post NHSBSA ‘Hints & Tips’ – Issue 56 appeared first on Community Pharmacy England.

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 17 Issue 12 July 2024) has been published and includes articles on: Epimax Ointment and Epimax Paraffin-Free Ointment: reports of ocular surface toxicity and ocular chemical injury Letters and medicine recalls sent to healthcare professionals in June 2024. To see the latest [...]

The post MHRA Drug Safety Update: July 2024 appeared first on Community Pharmacy England.

In response to significant ongoing disruption to the supply of some Quetiapine tablets, the Department of Health and Social Care (DHSC) has issued nine new Serious Shortage Protocols (SSPs). The nine new SSPs, introduced with immediate effect, allow community pharmacists to consider different options to enable continued supply of quetiapine tablets to mitigate the ongoing [...]

The post Nine SSPs issued for Quetiapine tablets appeared first on Community Pharmacy England.

Class 4 Medicines Defect Information: Propantheline Tablets 15mg (Genesis Pharmaceuticals livery (Chelonia Healthcare Limited)) Drug alert number: EL (24)A/27 Date issued: 9 July 2024 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Propantheline Tablets 15mg (Genesis Pharmaceuticals livery (Chelonia Healthcare Limited)) Company name: Chelonia Healthcare Limited [...]

The post MHRA Class 4 Medicines Defect Information: Propantheline Tablets 15mg (Genesis Pharmaceuticals livery (Chelonia Healthcare Limited)) appeared first on Community Pharmacy England.

The Department of Health and Social Care (DHSC) has redetermined the July 2024 reimbursement price for Naltrexone 50mg tablets (28) listed in Category A of the Drug Tariff. The basic price for this product should be £82.15 instead of £774.23 as published in the July Drug Tariff. This pricing issue was caused by a data [...]

The post July 2024 reimbursement price change for Naltrexone 50mg tablets appeared first on Community Pharmacy England.